Exploring Adenosine Receptor Ligands: Potential Role in the Treatment of Cardiovascular Diseases

被引：17

作者：

Geldenhuys, Werner J. ^{[1
]}

Hanif, Ahmad ^{[1
]}

Yun, June ^{[2
]}

Nayeem, Mohammed A. ^{[1
]}

机构：

[1] West Virginia Univ, Sch Pharm, Dept Pharmaceut Sci, Morgantown, WV 26506 USA

[2] Northeast Ohio Med Univ, Coll Med, Dept Integrat Med Sci, Rootstown, OH 44272 USA

来源：

MOLECULES | 2017年 / 22卷 / 06期

基金：

美国国家卫生研究院;

关键词：

atherosclerosis; myocardial infarction; cardiac death; vascular tone; SOLUBLE EPOXIDE HYDROLASE; SMOOTH-MUSCLE CELLS; MONOAMINE-OXIDASE-B; PROTEIN-KINASE-C; K-ATP CHANNELS; A(2A) RECEPTOR; CYP-EPOXYGENASES; AORTIC RELAXATION; A(1); ANTAGONISTS;

D O I：

10.3390/molecules22060917

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cardiovascular diseases remain the number one diseases affecting patients' morbidity and mortality. The adenosine receptors are G-protein coupled receptors which have been of interest for drugs target for the treatment of multiple diseases ranging from cardiovascular to neurological. Adenosine receptors have been connected to several biological pathways affecting the physiology and pathology of the cardiovascular system. In this review, we will cover the different adenosine receptor ligands that have been identified to interact with adenosine receptors and affect the vascular system. These ligands will be evaluated from clinical as well as medicinal chemistry perspectives with more emphasis on how structural changes in structure translate into ligand potency and efficacy. Adenosine receptors represent a novel therapeutic target for development of treatment options treating a wide variety of diseases, including vascular disease and obesity.

引用

页数：11

共 35 条

[1] A3 adenosine receptor: Homology modeling and 3D-QSAR studies [J].

Almerico, Anna Maria ;

Tutone, Marco ;

Pantano, Licia ;

Lauria, Antonino .

JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2013, 42 :60-72

[2]

Atef R. M., 2017, MOL NEUROBIOL, P1, DOI [10.1007/s12035-017-0401-128120151, DOI 10.1007/S12035-017-0401-128120151]

[3] Adenosine receptors as drug targets - what are the challenges? [J].

Chen, Jiang-Fan ;

Eltzschig, Holger K. ;

Fredholm, Bertil B. .

NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) :265-286

[4]

de Lera RM, 2014, J MED CHEM, V57, P3623, DOI DOI 10.1021/JM4011669

[5] Supraventricular tachycardia [J].

Delacrétaz, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1039-1051

[6] Istradefylline: First Global Approval [J].

Dungo, Rosselle ;

Deeks, Emma D. .

DRUGS, 2013, 73 (08) :875-882

[7]

Gillespie C. D., 2012, NCHS DATA BRIEF, V103, P1

[8] Structure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity [J].

Glukhova, Alisa ;

Thal, David M. ;

Nguyen, Anh T. ;

Vecchio, Elizabeth A. ;

Jorg, Manuela ;

Scammells, Peter J. ;

May, Lauren T. ;

Sexton, Patrick M. ;

Christopoulos, Arthur .

CELL, 2017, 168 (05) :867-+

[9] Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists [J].

Harmse, Rozanne ;

van der Walt, Mietha M. ;

Petzer, Jacobus P. ;

Terre'Blanche, Gisella .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (24) :5951-5955

[10] The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist [J].

Jaakola, Veli-Pekka ;

Griffith, Mark T. ;

Hanson, Michael A. ;

Cherezov, Vadim ;

Chien, Ellen Y. T. ;

Lane, J. Robert ;

IJzerman, Adriaan P. ;

Stevens, Raymond C. .

SCIENCE, 2008, 322 (5905) :1211-1217

← 1 2 3 4 →